| Company
| University/Non Profit
| Type of Agreement
| Product Area
| Details Month
|
| Abgenix Inc. (subsidiary of Cell Genesys Inc.)
| CV Cancer Center [Ronald Billing]
| License
| ABX-CBL antibody (a.k.a. CBL-1) that is currently in Phase II trials for graft vs. host disease (GVHD)
| Abgenix acquired rights to anti- body and will continue Phase II trials in GVHD after completing confirmatory study required by change in manufacturing process; Abgenix will also evaluate product in kidney and other organ transplant rejection indications (3/97)
|
| Advanced Viral Research Corp. (NASDAQ:ADVR)
| National Cancer Institute (NCI) of the National Insti- tutes of Health [Howard Young]
| CRADA/MTA (Cooperative Research and Development Agreement/ Material Transfer Agreement)
| Collaboration on molecular mecha- nism by which Retic- ulose (a peptide nucelic acid product) affects transcription of gamma interferon gene
| Details ND (3/97)
|
| Affymetrix Inc., Millennium Pharmaceuticals Inc. and Bristol- Meyers Squibb Co. (NYSE:BMY)
| The Whitehead Institute/Massachu- setts Institute of Technology Center for Genome Research [Eric Lander]
| Consortium
| Research program in functional geno- mics (to develop the next generation of genomics technol- ogies)
| Companies formed consortium to fund 5-year investigator-initiated research program (total $40M at $8M/year); Whitehead gets access to Millennium and Affymetrix technologies; companies get cer- tain licensing rights to develop- ments funded by consortium or emerging from use of contributed technology (4/97)
|
| Agouron Pharma- ceuticals Inc.
| The University of Newcastle-Upon- Tyne (U.K.) and Cancer Research Campaign Technol- ogy (CRCT; U.K.)
| License; research collaboration
| Development of anticancer drugs based on CRCT¿s prototype inhibitors of poly ADP-ribose polymerase (PARP; plays key role in chemotherapy drug- resistance of tumors)
| Agouron acquired license to PARP and will support research at New- castle, contribute its expertise in structural analysis and optimize and develop PARP inhibitors; CRCT gets milestones and royal- ties if Agouron commercializes PARP inhibitors (10/97)
|
| Agritope Inc. (unit of Epitope Inc.)
| Salk Institute for Biological Studies
| Option on license; collaboration
| Evaluation of 5 different plant genes discovered by Salk (confer enhanced agronomic traits)
| Agritope will evaluate genes and has exclusive option to license them for use in fresh fruit and vegetables; Agritope will also genetically engineer prototype commercial plant varieties con- taining these genes and evaluate their utility in field applications (3/97)
|
| American Biogen- etic Sciences Inc.
| The Chinese Academy of Med- ical Sciences (Peoples Repub- lic of China)
| Strategic alliance
| Use of American Biogenetics anti- gen-free technology to produce monoclo- nal antibodies of superior affinity and specificity
| Alliance expands cooperative relationship established 9/93; Chinese Academy gets rights to technology; American Biogenetic gets rights to develop and commer- cialize diagnostic and therapeutic products (7/97)
|
| Antex Biologics Inc. (NASDAQ: ANTX)
| Defense Advanced Research Projects Agency
| Contract
| Use of Antex¿s Nutriment Signal Transduction tech- nology to develop small molecule inhibitors of patho- gensis in bacteria (modulate expres- sion of virulence factors)
| Details ND (5/97)
|
| ArQule Inc.
| University of California San Francisco [Charles Craik]
| Sponsored research agreement
| Viral protease inhib- itors; initial thera- peutic targets are Kaposi¿s sarcoma herpes virus pro- tease, cruzain (pro- tease in Chagas dis- ease) and HIV pro- tease
| ArQule will assess and select com- pounds from its Mapping Array program using UCSF¿s crystal structures and biochemical assays for proteases; active leads will be optimized via ArQule¿s Directed Array program; ArQule will spon- sor research and gets exclusive licensing rights to any new tech- nology as well as new drug can- didates (7/97)
|
| ArQule Inc.
| University of South- ern California [Nicos Petasis]
| License
| Set of chemistries for the practical synthesis of alpha- amino acids from or- ganoboronic acids
| ArQule will use chemistries to synthesize compounds for its Mapping Array and Directed Array Programs; additional details ND (12/97)
|
| Aurora Bio- sciences Corp.
| University of Cal- ifornia San Diego [Atsushi Miyawaki; Roger Tsien]
| License
| Fluorescent reporter system for measur- ing intracellular sig- naling; chameleon indicators are report- ers of free intracellular calcium concentration
| Aurora gets exclusive worldwide license; further details ND (10/97)
|
| Biora AB (Sweden)
| University of Gothenburg [Jan Lindhe]
| Research collaboration
| Preclinical and early clinical studies on new indications for Emdogain (porcine protein that mimics human pro- tein amellogenin, or enamel matrix der- ivative; approved for periodontal uses)
| 5-year agreement; clinical studies will be conducted at the university (6/97)
|
| Biora AB (Sweden)
| Centre of Oral Biol- ogy at the Karolin- ska Institute in Stock- holm
| License
| Amelin, a protein present during norm- al tooth development in humans
| Biora acquired patent rights and will investigate the poss- ibility of using the protein in dental surgery (12/27)
|
| Biota Holdings Ltd. (ASX:BTA; Australia)
| Biomolecular Research Institute (Australia)
| Alliance
| Use of structure- based design to create new drug molecules targeted at specific viral structures; initial focus on respiratory syncytial virus
| Biota will pay access fee and royalties on a project-by-project basis (7/97)
|
| Biota Holdings Ltd. (ASX:BTA; Australia)
| Commonwealth Scientific Industrial Research Organiz- ation (CSIRO; Australia) [Colin Ward; Peter Colman]
| Extension of research collaboration
| Development of orally active treat- ment for diabetes (replacement for injectable insulin) via structure-based drug design
| Agreement will be extended for 1 more year (7/97)
|
| Biota Holdings Ltd. (ASX:BTA; Australia)
| La Trobe Univer- sity (Australia) [Les Deadly; Anthony Kaye]
| License
| Newly synthesized chemical anticancer compounds that can simultaneously inhib- it 2 enzymes involved in DNA replication
| University researchers will con- duct further research before lead compound is selected; Biota will fund development through Phase I trials and gets exclusive worldwide rights to any products (4/97)
|
| Biovector Thera- peutics SA* (France)
| INSERM (French National Institute of Health and Medical Research)
| License
| Chimeric cytomeg- alovirus (CMV) pro- tein (consists of reg- ulatory and matrix proteins) coupled with supramolecular biovector (for use as CMV vaccine)
| Biovector Therapeutics gets exclusive license for use of joint patent (11/97)
|
| Briana Bio-Tech Inc. (VSE:BIA; Canada)
| University of Alberta, Multiple Sclerosis Research Clinic (Canada) [Joel Weiner]
| License
| Synthetic peptide technology for treat- ing chronic progres- sive multiple sclero- sis; peptide suppres- ses antibodies that bind to and degrade myelin basic protein
| Briana gets exclusive worldwide license to peptide technology plus option to license related technol- ogies; Briana will provide US$0.46M to fund 1st year of clinical research studies and paid US$0.18M upfront license fee; Briana will provide additional US$1.58M for next 3 years of clin- ical studies; company will also conduct all clinical trials in Can- ada and elsewhere toward product approval and will pay milestones and royalties to university (prices converted at ratio of C$1.42/US$1) (letter of intent 5/97; finalized 10/97)
|
| Cadus Pharma- ceutical Corp.
| National Jewish Center for Immu- nology and Respir- atory Medicine [Gary Johnson; John Cambier]
| License; research collaboration
| Signal transduction technologies related to allergic inflamma- tion, cancer, other diseases; includes interleukin-convert- ing enzyme (ICE)- like protease and certain genes
| Parties expanded 11/94 agreement; Cadus now has rights to license all signal transduction technolog- ies, subject to terms of 11/94 agreement; Cadus made certain payments (5/97)
|
| Cantab Pharma- ceuticals plc (U.K.)
| Marie Curie Cancer Center (U.K.) [Peter OHare]
| Joint venture company, Phogen Ltd.
| 50:50 joint venture to evaluate and develop herpesvirus structural protein VP22 as drug deliv- ery mechanism (for intracellular trans- port of peptides, proteins and DNA)
| Phogen gets license to VP22 tech- nology and underlying intellectual property; Cantab will fund Phogen R&D for 1st 2 years; Cantab gets exclusive access to applications of VP22 for immunomodulation of cancer and infectious diseases; specific financial details ND (2/97)
|
| Cell Genesys Inc.
| National Cancer Institute
| Research collaboration; option agreement
| Development of gene therapies for ovarian, breast, colon, lung and prostate cancer
| Details ND (1/97)
|
| Cell Genesys Inc.
| Dana Farber Can- cer Institute
| Research collaboration; option agreement
| Development of gene therapies for ovarian, breast, colon, lung and prostate cancer
| Details ND (1/97)
|
| Cell Genesys Inc.
| Arizona Cancer Center at the University of Arizona
| Research collaboration; option agreement
| Development of gene therapies for ovarian, breast, colon, lung and prostate cancer
| Details ND (1/97)
|
| Cel-Sci Corp.
| The American Red Cross
| Supply agreement
| Human white blood cells for pro- duction of immune booster Multikine (natural mixture of human cytokines)
| Partners entered into long-term supply agreement; further details ND (8/97)
|
| Cel-Sci Corp.
| National Cancer Institute
| CRADA
| Ligand Epitope Antigen Presenta- tion System (LEAPS) heterocon- jugate technology for prostate and breast cancer im- munotherapeutics
| CEL-SCI and NCI will jointly test LEAPS technology in NCI animal models for prostate and mammary cancers (12/97)
|
| CoCensys Inc.
| The University of Saskatchewan (Canada)
| License
| Small molecule compounds (sodium channel blockers) with analgesic and anti- epileptic activities; lead candidate is CO 102862
| CoCensys will pay license fee, milestones and royalties; CoCen- sys will also sponsor research for 3 years (10/97)
|
| CollaGenex Pharmaceuticals Inc.
| National Cancer Institute
| Extension of research collaboration inhibitor) for cancer
| Development of Metastat (matrix metalloproteinase therapy
| Partners will collaborate on clinical development (6/97)
|
| CombiChem Inc. (IPO pending)
| University of Pittsburgh [Dennis Curran]
| Option agreement; sponsored research
| Use of fluorous syn- thesis and separation technologies for multi-parallel syn- thesis of chemical libraries
| CombiChem gets exclusive option to license rights to patent for use in specified fields; CombiChem will also sponsor research in this area (9/97)
|
| Cortecs Internation- al Ltd. (U.K.)
| Defense Evaluation Research Agency (DERA; U.K.)
| Research agreement
| Research on use of Cortecs Macro- mune oral drug de- livery system as vehicle for Yersinia pestis F1 and V antigens (oral vaccine against the plague [both bubonic and pneumonic], potential biological weapon)
| Agreement extends the 6/96 pact between the parties under which DERA tested Cortecs¿ system in a mouse model; further details ND (3/97)
|
| Cytel Corp.
| Institute for Biol- ogical Sciences of the National Re- search Council of Canada
| License
| Enzyme technology for efficient product- ion of bacterial glycosyltransferases
| Cytel gets exclusive license to certain enzyme technology in return for licensing fees and roy- alties on product sales; Cytel¿s Glytec unit will use technology to aid in synthesis of bioactive carbohydrates (5/97)
|
| Dendreon Corp.* (formerly Activated Cell Therapy Inc.)
| The Mayo Clinic
| Research collaboration
| Mayo Clinic will initiate Phase I/II clinical trial using Dendreon¿s dendri- tic cell therapy for treating advanced prostate cancer (therapy activates killer T cells)
| Dendreon will establish a cell processing facility at the Mayo Clinic, which the two parties will own jointly; financial details ND (10/97)
|
| Diversa Corp.* (formerly Recombinant Biocatalysis Inc.)
| Bogor Agricultural University (Indonesia)
| Bio- prospecting agreement
| Isolation and col- lection of micro- organisms from Indonesia¿s diverse habitats to search for enzymes with industrial and phar- maceutical uses
| 2-year agreement; Diversa will assist university in establishing a Center for Microbial Diversity; university gets royalties on any products developed and commer- cialized from research (9/97)
|
| Diversa Corp.* (formerly Recombinant Biocatalysis Inc.)
| Yellowstone National Park
| Bio- prospecting agreement
| Identification of lead drug com- pounds from micro- organisms collect- ed and isolated from thermal springs
| 5-year agreement; Diversa will pay annual fee and in exchange gets access to certain areas within Yellowstone National Park for bioprospecting; Diversa has rights to commercialize any products (8/97)
|
| Dyax Corp.*
| Massachusetts Institute of Tech- nology [Harvey Lodish; Perry Bickel; Phillip Scherer]
| Research collaboration
| Subtractive Anti- body Screening (SAS) technology for identifying and cloning therapeutic and diagnostic targets (enables identification of cell- specific cell-surface and secreted proteins)
| Details ND (9/97)
|
| EntreMed Inc.
| Children¿s Hospital (affiliate of Harvard Medical School) [Robert D¿Amato]
| License
| License on 2-meth- oxyestradiol (natural estrogen metabolite) which inhibits growth of breast cancer cells and blocks angiogenesis
| EntreMed gets worldwide rights to product; National Cancer Institute (which collaborated with Children¿s Hospital on preclinical work) will extend pre-clinical and clinical development in collaboration with EntreMed (1/97)
|
| EntreMed Inc.
| National Cancer Institute
| Two letters of intent on research collaboration
| Development of anti-angiogenic drug therapies for use in preclinical and clinical studies; includes Endostatin (natural anti-angio- genic protein) and 2-methoxyestradiol (2-ME; natural oral- ly active estrogen metabolite) as well as 2-ME synthetic analogues
| Partners will evaluate various manufacturing processes for Endo- statin; will also evaluate the com- pound in preclinical studies; 2-ME and its analogues will be evaluated in animal models; both letters of intent are for 1 year and will allow immediate initiation of studies while CRADAs are being final- ized (8/97)
|
| Ergo Science Corp.
| Massachusetts General Hospital
| License
| New therapeutic approaches for treat- ing diseases assoc- iated with immune system dysfunction (type of compound or molecule not described)
| Ergo Science gets exclusive license to series of patents; further details ND (4/97)
|
| Genelabs Technol- ogies Inc.
| University of California San Francisco [John Fahy]
| Research collaboration
| Clinical study of the association of asthma with 50 gene candidates identified by Genelabs (by positional cloning) from an asthma locus on chromosome 5
| Clinical study will determine whether the expression of these genes is altered in atopic asthma patients compared to healthy individuals; further details ND (7/97)
|
| Gene Logic Inc.
| Baylor College of Medicine (Prostate Center)
| Research collaboration
| Identification of genes associated with development and progression of prostate cancer
| Baylor will provide its library of tumor and normal prostate cell samples; Gene Logic will evaluate patterns of gene expression and regulation in these samples via its functional genomics technology; Gene Logic will own commercial rights to all genes discovered (1/97)
|
| Gene Logic Inc.
| Center for Clinical and Basic Research (CCBR; Denmark)
| Research collaboration
| Discovery of new genes related to osteoporosis
| CCBR will provide normal and osteoporotic human bone samples as well as tissues from animal models for analysis via Gene Logic¿s functional genomics technologies; further details ND (1/97)
|
| Gene Logic Inc.
| The Johns Hopkins University [Robert Yolken]
| Research collaboration
| Discovery of genes associated with schizophrenia and depression
| Johns Hopkins will provide its library of brain tissue samples obtained post-mortem from indi- viduals with schizophrenia, bipolar disorder or severe depression; Gene Logic will create series of molecular topographies that show changes in gene expression pat- terns in these samples; financial terms ND (4/97)
|
| Gene Logic Inc.
| The Johns Hopkins University School of Medicine [Jay Shapiro]
| Research collaboration
| To discover genes associated with osteoporosis via Gene Logic¿s gen- omics and bioinfor- matics platforms
| Gene Logic gets access to normal and diseased bone samples from patients undergoing surgery; further details ND (5/97)
|
| GeneMedicine Inc.
| University of California San Francisco [Donald McDonald]
| Research collaboration
| Development of gene medicines for treating cancer by inhibiting angiogen- esis (via GeneMed- icine¿s non-viral gene delivery form- ulations)
| GeneMedicine will sponsor Mc- Donald¿s research, which involves methods for assessing 3-D organ and cellular distribution of form- ulated DNA complexes in vivo; GeneMedicine has option for exclusive license to any discover- ies (7/97)
|
| Genentech Inc.
| Cardiovascular Re- search Center at Massachusetts Gen- eral Hospital
| Collaboration
| Basic developmen- tal biology research using zebrafish as model organism; especially to identi- fy genes that play key roles in develop- ment of cardiovas- cular, gastrointestinal and nervous systems
| Genentech will fund this multiyear collaboration (for undisclosed amount); the 1st goal of the collab- orators is to make publicly avail- able a map of all identified mark- ers in zebrafish genome (2/97)
|
| Genome Thera- peutics Corp.
| Creighton University School of Medicine
| Collaboration; license
| To identify and characterize genes for treating osteo- porosis; initially to clone and character- ize newly discovered gene associated with high bone mass (monogenic trait; may protect against or reverse osteopor- otic process)
| Genome Therapeutics gets exclu- sive license to high bone mass (HBM) gene; Creighton will collect and analyze DNA samples and histories from multi-generat- ional family; parties will collab- orate on localizing, identifying and characterizing HBM gene; financial terms ND (4/97)
|
| Genset SA (France)
| Hospital Parmenio Pinero and the Cam- pomar Research Foundation (Argentina) [Dr. LaJonquiere]
| Collaborative network
| Collection, bank- ing and analysis of DNA samples from patients affected with central nervous system disorders (2M patient files)
| Genset gets exclusive right to patent any genes and to all commercial applications that result; financial terms ND (6/97)
|
| Genset SA (France)
| INSERM (National Institute for Health and Medical Research; France)
| Joint research laboratory
| Research in fun- ctional genomics; use of mouse models for functional anal- ysis of genes identi- fied by Genset¿s integrated genomics technologies
| Joint laboratory will get support from University of Rennes and the Brittany regional government; two partners and regional govern- ment will contribute aggregate US$12M (FF60M) over 3 years; Genset and INSERM will jointly own all inventions; Genset will manage patent filings and gets exclusive worldwide licenses for all applications; INSERM gets royalties on product sales (2/97)
|
| Genset SA
| Royal College of Surgeons in Ireland (RSCI)
| Research collaboration; joint venture, Surgen
| Large-scale cardio- vascular genomics research (via assoc- iation studies based on human clinical data)
| Partners have formed 50/50 joint venture (Surgen) which will col- lect samples from tens of thous- ands of patients and process them for DNA banking; Genset will perform genome-wide studies of random, unrelated individuals and analyze genes associated with cardiovascular disease; Genset gets exclusive access to DNA bank for genomics and pharmacogenomics studies; Genset owns all rights and data generated from studies (10/97)
|
| (France)
|
|
|
|
|
| Genset SA (France)
| Technicon Bruce Rappaport Faculty of Medicine (Israel) [Nadine Cohen- Elbaz]
| Research collaboration
| Collection, banking and analysis of DNA from patients affected with common diseases; focus on large families that have homogeneous background and are representative of well-characterized ethnic groups
| 2-year agreement; Genset gets exclusive rights to patent any genes and to all commercial applications; financial terms ND (6/97)
|
| Genzyme Corp.
| Partners HealthCare System (including Brigham and Women¿s Hospital and Massachusetts General Hospital)
| Basic and clinical research alliance
| Fundamental sci- entific research and clinical trials
| Genzyme and its divisions get access to expertise in design and management of clinical trials as well as access to research under- way at Partners affiliated institu- tions; Genzyme also gets access to patient base; Partners gets access to Genzyme¿s expertise and abil- ities to commercialize products (9/97)
|
| Genzyme Molecu- lar Oncology (business unit of Genzyme Corp.)
| The Johns Hopkins University School of Medicine [Kenneth Kinzler]
| Research collaboration
| Use of SAGE tech- nology (serial anal- ysis of gene expres- sion) to identify and analyze gene expres- sion patterns in cancer
| Johns Hopkins Kinzler is co- inventor of SAGE technology; Genzyme Molecular got exclusive license to SAGE as part of Gen- zyme¿s 6/97 acquisition of Phar- maGenics Inc.; in this 5-year alliance, Genzyme Molecular will have access to all SAGE-related discoveries and inventions (7/97)
|
| Genzyme Molecu- lar Oncology (business unit of Genzyme Corp.)
| Massachusetts General Hospital
| Research collaboration
| Development of gene therapy for treating chronic hepatitis B (HBV) infection and cancer of the liver
| Genzyme will fund R&D and will provide adenoviral vector constructs for intracellular production of certain HBV proteins that interfere with viral replication in liver; Genzyme Mol- ecular will use monoclonal anti- bodies developed at Mass. General to target human liver cancer cells with cationic lipid-based vectors (6/97)
|
| Genzyme Molecu- lar Oncology (business unit of Genzyme Corp.)
| National Cancer Institute (NCI)
| Research collaboration
| Use of NCI¿s array of 60 cell- based screens to evaluate Genzyme¿s 1-million-com- pound library for those with anti- cancer activity
| The parties will negotiate a clin- ical development agreement for each active compound they agree to develop; Genzyme Molecular Oncology retains all commercial rights to lead compounds (7/97)
|
| Genzyme Trans- genics Corp.
| National Cancer Institute (NCI)
| CRADA
| Expansion of R&D on idiotypic cancer vaccines (currently in Phase I trials as adjunct to chemo- therapy in patients with B-cell lymph- oma or multiple myeloma)
| This 5-year CRADA expands on Phase I trials at NCI; Genzyme Transgenics, which has made these vaccines for NCI for past 4 years, will optimize and expand vaccine production process; Gen- zyme Transgenics will also fund expansion of ongoing trial and gets right to license the vaccines (4/97)
|
| Geron Corp.
| The Johns Hopkins University School of Medicine [John Gearhart]
| License; research collaboration
| Technology to isolate and characterize human primordial stem cell lines as well as identify factors that will direct the differentiation process
| Details ND (9/97)
|
| HemaSure Inc. and In-Line Diagnostics Co.*
| The American Red Cross
| Letter of intent to develop product
| Non-invasive anemia screening device for use with blood donors (based on In-Line¿s trans- cutaneous hemato- crit technology)
| HemaSure will fund product de- velopment and gets exclusive rights (from In-Line) to use tech- nology in blood banking business (3/97)
|
| Human Genome Sciences Inc.
| St. Elizabeth¿s Medical Center of Boston, Cato Hold- ing Co. and Jeffrey Isner
| Joint venture company, Vascular Genetics Inc.
| Gene therapy pro- ducts for treating vascular diseases; 1st gene therapy candidate based on VEGF-2 gene (vascular endothe- lial growth factor; active in formation of new blood vessels)
| Human Genome discovered VEGF- 2 gene and has transferred gene therapy rights exclusively to Vas- cular Genetics; new company also has rights to develop 2 additional genes in field of vascular disease from Human Genome¿s gene dis- covery program; Human Genome owns 19.9 0.000000e+00quity in Vascular Genetics and gets warrants for an additional 5.1 0.000000e+00quity; Human Genome alone has option to buy 1000f company; Cato Holding has 40.1take, St. Elizabeth¿s has 20take and Jeffrey Isner has 20take; Human Genome has option to manufacture VEGF- 2 and 2 future genes for a fee and also gets royalties on future pro- duct sales (11/97)
|
| Hyal Pharmaceuti- cal Corp. (NASDAQ: HYALF; Canada)
| McMaster Univer- sity (Canada) [Francoise Winnik]
| Research collaboration
| Use of hyaluronan induced targeting (HIT) technology in conjunction with magnetic resonance imaging for early detection of breast cancer
| Hyal and Natural Sciences and Engineering Research Council of Canada will jointly fund research project (total US$1.06M); Hyal will contribute US$0.7M over 3 years (prices converted at ratio of C$1.42/US$1) (10/97)
|
| Hybridon Inc.
| The Institute of Human Virology [Robert Gallo]
| Research collaboration
| Continuation of development of oligonucleotide- based antisense therapies for HIV and AIDS, with an expansion into chemokine receptors as cofactors of infec- tion and into human herpes virus 6 in immunocompromised patients
| 5-year agreement; further details ND (5/97)
|
| Hyseq Inc.
| Conservation International
| Partnership
| Use of functional genomics to support Conservation Inter- national¿s bio- prospecting as well as preservation of biodiversity (espec- ially in rainforests)
| Conservation International will use gene sequencing technology to search for wild plants and organ- isms as sources of new medicines and crops (bioprospecting); Hyseq will give part of any product revenues to conservation efforts in country where project occurs (3/97)
|
| ID Vaccine Corp. (subsidiary of ID Biomedical Corp.; TSE:IDB; Canada)
| National Institute of Allergy and Infectious Diseases (NIAID)
| Clinical research collaboration
| Testing of ID Vac- cines Group A Streptococcus subunit vaccine
| ID Vaccine will manufacture pro- duct and supply it to NIAID for initial human trials; NIAID will file IND and conduct Phase I trials; each party will cover its own expenses (10/97)
|
| ID Vaccine Corp. (subsidiary of ID Biomedical Corp.; TSE:IDB; Canada)
| University of British Columbia [B. Brett Finlay]
| Research collaboration
| Development of vaccines for bact- erial infections, including entero- pathogenic and enterohemorrhagic Escherichia coli
| ID Vaccine gets option on exclu- sive worldwide license to technol- ogy (not described) for all vaccine uses (6/97)
|
| ID Vaccine Corp. (subsidiary of ID Biomedical Corp.; TSE:IDB; Canada)
| Albert Einstein College of Medicine of Yeshiva University [Arye Rubinstein]
| License
| Subunit vaccine for HIV containing por- tions of the gp 120 surface molecule of six different strains of HIV-1
| ID Vaccine licensed rights; Phase I trials are slated to begin in Brazil in the third quarter of 1998 (12/97)
|
| ImClone Systems Inc.
| Mario Negri Institute (Italy) [Elisabetta Dejana]
| License; research collaboration
| Development of small molecule and antibody-based inhibitors to protein VE-capherin-2 (thought to enable formation of capil- lary blood vessel network in solid tumors)
| ImClone acquired exclusive rights to protein and also initiated collab- oration on pharmaceutical research (11/97)
|
| ImmuCell Corp.
| U.S. Navy [Stephen Savarino]
| CRADA
| Conduct Phase II field study of TravelGAM (bovine anti-Escherichia coli immunoglobu- lins; for preventing diarrhea) in multi- national military exercise to be con- ducted in the Middle East
| Details ND (4/97)
|
| InSite Vision Inc.
| University of Connecticut Health Center
| License
| Gene for primary congenital glaucoma
| InSite exercised its option on an exclusive worldwide license to gene for diagnostic uses; partners are developing a diagnostic kit (8/97)
|
| InSite Vision Inc.
| University of Rochester
| License
| Device for non- surgical, controlled delivery of ophth- almic drugs to retina and other tissues in back of eye
| InSite Vision gets exclusive worldwide license; further details ND (8/97)
|
| Interferon Sciences Inc.
| The American Red Cross
| Supply agreement
| Human source leukocytes for pro- duction of Alferon N Injection (multi- species alpha inter- feron; FDA-approved for treating certain types of genital warts)
| American Red Cross will supply human luekocytes to Interferon Sciences; further details ND (4/97)
|
| Ion Pharmaceuti- cals Inc. (wholly owned subsidiary of Sheffield Medi- cal Technologies Inc.)
| Children¿s Hospital Boston [Carlo Brugnara]
| License; renewal of sponsored research agreement
| Patents related to use of certain com- pounds, including clotrimazole (anti- fungal drug) for treating sickle cell anemia
| Ion exercised its option to license series of patents, on which it now has worldwide rights to develop and sublicense clotrimazole, its metabolites and other compounds; Ion will also continue to fund re- search at Children¿s Hospital (1/97)
|
| Isis Pharmaceuti- cals Inc.
| Defense Advanced Research Projects Agency (DARPA)
| Contract
| Discovery of broad- spectrum antibac- terial small molecule drugs that inhibit essential molecular interactions between RNA and proteins that are critical to bacterial life cycle
| Details ND (4/97)
|
| Isis Pharmaceuti- cals Inc.
| University of Cali- fornia San Francisco [Thomas James]
| Research collaboration
| Characterization and targeting of particu- lar HIV-1 genes via combinatorial chem- istry and structure- based drug design; in particular, to de- termine molecular structures that interfere with TAR- tat (RNA-protein) interactions
| Partners have been jointly award- ed research grant from the Univer- sity¿s Biotechnology Strategic Targets For Alliances In Research (BioSTAR) project; further details ND (1/97)
|
| Lexicon Genetics Inc.*
| The Merck Genome Research Institute
| Research agreement
| Large-scale analysis of gene function via Lexicon¿s Omni- Bank library of 500,000 mouse clones engineered to contain modifications in every gene in mammalian genome
| Merck Genome Research Institute will support creation of 150 new mouse models to be distributed on not-for-profit basis to scientific community; Lexicon will get $8M over 5 years (4/97)
|
| LifeCell Corp.
| U.S. Army Institute of Surgical Research
| Cooperative agreement
| Development of tissue transplant pro- ducts for use in neurological, derma- tological and cardio- vascular surgery (AlloDerm grafts)
| LifeCell awarded $1.07M over 2 years in product development funding; LifeCell will also use its tissue preservation technology to develop vascular grafts for bypass surgery (1/97)
|
| Medarex Inc.
| Utrecht University (the Netherlands) [Jan G.J. van de Winkel]
| Strategic alliance
| Therapeutics for cancer, autoimmune disorders and infect- ious diseases (based on Fc receptors)
| Medarex Europe B.V. will provide $0.5M/year for 4 years for R&D; Medarex Europe gets rights to all technology and products (1/97)
|
| MediChem Research Inc.*
| State of Sarawak, Malaysia
| Joint venture company, Sarawak Pharma- ceuticals MediChem Inc.
| Clinical development of anti-HIV compound Calanolide A (isolated from Calophyllum lanigerum tree found in Sarawak rain forest); compound is a non- nucleoside inhibitor of HIV
| Company will begin U.S. clinical trials when cleared by FDA; MediChem has worldwide exclu- sive license on compound from National Cancer Institute which discovered it in an anti-HIV screening program (4/97)
|
| MegaBios Corp.
| National Jewish Center for Immu- nology and Res- piratory Medicine [Steve Dow]; University of Colorado Health Sciences Center [Pat Walsh]
| License; research collaboration
| Use of certain un- named immunostim- ulatory genes for treating melanoma and other solid tumors (delivered via MegaBios¿ non- viral gene therapy technology)
| MegaBios gets exclusive license to genes; company will finance completion of initial clinical study (under physician-sponsored IND) and will partner product for full- scale clinical development and commercialization (11/97)
|
| Micrologix Bio- tech Inc. (TSE: MBI; Canada)
| British Columbia Cancer Agency [Marcel Bally]
| Research collaboration
| Study of the anti- cancer therapeutic potential of Micro- logixs cationic peptides
| Micrologix and The Medical Re- search Council of Canada will fund research in animal models of malignant disease (9/97)
|
| Micrologix Bio- tech Inc. (TSE: MBI; Canada)
| Innovation and Development Corp. of the University of Victoria
| License
| Method for increas- ing efficiency of bacterial production of cationic antimicro- bial peptides
| Micrologix gets exclusive world- wide license to pending patents (5/97)
|
| MitoKor Inc.*
| University of California San Diego [Jerrold Olefsky]
| Research collaboration
| Mitochondrial defects and etiology of non-insulin dependent diabetes mellitus (Type II)
| MitoKor will provide $0.5M to fund research as part of Biotech- nology Strategic Targets for Alliances in Research Project (BioSTAR) (9/97)
|
| Molecular Dynamics Inc. and Amersham Life Science Ltd. (U.K.)
| Huntsman Cancer Institute and the University of Utah [Raymond White]
| Strategic collaboration
| Development of high-throughput DNA Microarray System for study of gene expression in complex biological systems
| Huntsman will fund research in exchange for early access to latest microarray technologies (6/97)
|
| Molecular Dynamics Inc. and Amersham Life Science Ltd. (U.K.)
| The Institute for Genomic Research (TIGR)
| Collaboration
| Development of high-throughput DNA Microarray System (measures gene expression in many types of cells)
| TIGR will participate in the Microarray Technology Access Program and provide collaborative expertise in exchange for early access to latest microarray technol- ogies (7/97)
|
| Mycogen Corp.
| Washington University [Roy Curtiss III]
| Licenses
| Technology to genetically alter plants to produce antigens that elicit immune response to disease (edible vaccines)
| Mycogen gets exclusive rights to human and animal health applica- tions of technology; Mycogen will sublicense human health rights and develop animal health applica- tions itself (11/97)
|
| Myriad Genetics Inc.
| Valley Mental Health (Utah)
| Research collaboration
| Development of database on central nervous system dis- orders and use of database (combi- ned with geneolo- gical database) to identify genes associated with these disorders
| Valley Mental Health has collected 100,000 anonymous patient rec- ords over 30 years; Myriad Gene- tics gets worldwide exclusive rights to diagnostic and therapeutic applications of data generated (11/97)
|
| NeoPharm Inc.
| National Institutes of Health (NIH) and FDA [Raj Puri]
| License; CRADA
| Development of chimeric human protein IL13-PE38- QQR (fusion of receptor-binding ligand interleukin- 13 with a derivative of Pseudomonas exotoxin [PE38Q- QR]); initially for treating kidney cancer
| NeoPharm gets exclusive world- wide license from NIH; NeoPharm also entered into CRADA with FDA for clinical and commercial development of product as anti- cancer agent (and to expand to other tumor types) (10/97)
|
| Northwest Neuro- Logic Inc.*
| Oregon Health Sciences University [Roger Cone]
| License
| Investigation of link between melanocortin (MSH) receptors in brain, eating behavior and obesity
| Northwest NeuroLogic gets exclusive license to melano- cortin receptors (1/97)
|
| Oncor Inc.
| The Johns Hopkins University School of Medicine
| License
| Patent for product that detects aberrant methylation of the glutathione-S-trans- ferase gene (GSTP1) promoter region (very early genetic change in development of prostate cancer)
| Oncor gets exclusive worldwide license on product for use in genetic diagnosis of prostate can- cer (this is 9th agreement between the parties in area of genomic cancer technology) (4/97)
|
| Oncor Inc.
| University of Heidelberg [Thomas Cremer]
| License
| High-throughput technology for re- moving repeat se- quences, if present, from DNA probes
| Oncor acquired license; additional details ND (12/97)
|
| OncorMed Inc.
| Cancer Research Campaign Tech- nology (CRCT; U.K.) and Duke University
| License
| BRCA2 gene and related discoveries
| OncorMed gets exclusive world- wide license for use in diagnostic products and services; CRCT and Duke are pursuing licensees for therapeutic applications; Oncor- Med will share in revenues gener- ated from therapeutic licenses (7/97)
|
| Onyx Pharma- ceuticals Inc.
| Lawrence Liver- more National Lab- oratory Genome Center [Greg Lennon; Joanna Albala]
| Research collaboration
| Development of functional genomics system that includes automated high- throughput methods for expressing and purifying proteins (Proteome Project)
| Lawrence Livermore has collection of arrayed cDNA libraries; the collection of proteins generated will facilitate identification of new therapeutic targets; 2-year collaboration funded under the Biotechnology Strategic Targets for Alliances in Research Project (BioSTAR) (8/97)
|
| OraVax Inc.
| St. Louis University [Thomas Chambers]
| License
| Chimeric flavivirus vaccine technology; combines genes required for replication of yellow fever YF 17D vaccine strain virus with genes for viral coat antigens of target virus (platform technology for OraVax¿s Chimeri- Vax vaccines)
| OraVax gets exclusive worldwide rights; further details ND (9/97)
|
| Ortec International Inc.
| New Jersey Center for Biomaterials and Medical Devices [Michael Dunn]
| Collaboration
| To develop 2nd gen- eration collagen matrix for use in pro- duction of Ortec¿s Composite Cultured Skin (CCS; currently in clinical trials for treating severe burns)
| Details ND (1/97)
|
| OXiGENE Inc.
| Arizona State University [George Pettit]
| Development agreement
| Development of Combretastatin A-4 as a prodrug for treating solid tumors; naturally occurring molecule is thought to inhibit angiogenesis
| OXiGENE gets option on exclu- sive worldwide royalty-bearing license (5/97)
|
| OXiGENE Inc.
| Boston Medical Center (affiliate of Boston University)
| Clinical trial and sponsored research agreement
| Clinical study of 3 deoxyadenosine (cor- dycepin) and 2-de- oxycorformycin (pentostatin) in patients with TdT-positive acute lymphoid leukemia
| Boston Medical Center will con- duct Phase I trial under IND spon- sored by National Cancer Institute; OXiGENE gets option for exclusive worldwide license for cordycepin (1/97)
|
| OXiGENE Inc.
| Joint Center for Radiation Therapy, Department of Radiation Oncology, Harvard Medical School and M.D. Anderson Cancer Center (University of Texas)
| Collaboration
| Research on OXi- GENEs compounds Oxi-104 and Neu- Sensamide; focus on tumor growth, apop- tosis and brain tumors
| Collaboration involves preclinical and clinical studies; universities will assist company in establishing clinical trial protocols (4/97)
|
| Paracelsian Inc.
| National Cancer Institute [Genoveffa Fran- Institute (NCI)
| CRADA
| Screening of Para- celsian's library of extracts of traditional chinese medicinal herbs for compounds that modulate cell signaling pathways involved in cancer and HIV infection
| The CRADA extends the 1995 letter of intent between the parties for 2 years (through 12/98) (1/97)
|
| Peptimmune Inc.
| Massachusetts General Hospital
| License option
| Peptimer, which are comprised of multiple linked peptide antigens that can more efficiently induce a highly specific T-cell response at a much lower dose than the same peptide antigen in its natural singular form.
| Peptimmune has an exclusive option to license patent pending Peptimer technology for use in developing selected p24 peptide antigens as a potential therapeutic HIV vaccine (12/97)
|
| Pharmacylics Inc
| National Cancer Institute (NCI)
| Collaboration
| Additional clinical trials of Pharmacylic's adjunct cancer treatments Gd Tex (gadolinium texaphyrin a radiation sensitizer and LuTex (lutetium texaphyrin a photosensitizer)
| Parteners will collaborate on design of clinical studies and selection of tumor indications; partners are also in progress of structuring a CRADA inder which NCI will sponser multiple clinical trials on both products(3/97)
|
| Sequana Thera- peutics Inc. (merged with Arris Pharmaceutical Corp. to form Axys Pharmaceuticals Inc.)
| Memorial Sloan- Kettering Cancer Center
| Formation of joint venture, Genos Biosciences Inc.
| Cancer genetics; to identify somatic mutations and related sequence data for use in prognosis, diagnosis and treat- ment of many com- mon cancers (init- ially breast, colon and prostate cancer)
| The joint venture will be a free- standing R&D company, to which each party will contribute $5M for initial funding; Sloan- Kettering will provide retrospective patient database of tumor-tissue samples and information on treatment outcomes, as well as data from ongoing clinical activiites; Sequana will provide its gene discovery platform and functional genomics technologies (letter of intent 8/96; definitive agreement 1/97)
|
| Seragen Inc. and Marathon Biopharmaceut- icals
| Boston University
| Sale of business unit/ creation of new company
| Contract develop- ment and GMP manufacturing
| After Seragen sold its operating division to Boston University, the unit was renamed Marathon Bio- pharmaceuticals; Marathon has contracts with BioChem Vaccines Inc., of Quebec, and with Seragen (12/97)
|
| Shanghai GeneCore BioTechnologies Co. Ltd. (GeneCore; joint venture of Sequana Thera- peutics Inc., The Perkin-Elmer Corp. and SiniWest Holdings Inc.)
| State Science and Technology Com- mission of China (consortium that includes the China National Center for Biotechnology Development, among others) (Peoples Republic of China)
| Research contract
| Sequencing of human genes for liver cancer
| Under terms of the government contract, GeneCore will use its high-throughput genomic sequen- cing and related technologies to identify and sequence genes; GeneCore gets research funds and milestone payments; specific terms ND (10/97)
|
| Sparta Pharmaceuticals Inc.
| Estate of Karl Beyer
| License
| Pyrazinoylguanidine (PZG)
| Sparta's Horizon Pharmaceuticals subsidiary will develop the drug candidate, which has poten- tial to treat a variety of chronic metabolic diseases, including Type II diabetes mellitus; Phase II testing begins in 1998 (12/97)
|
| SuperGen Inc.
| The Stehlin Foun- dation for Cancer Research
| License
| Anticancer drug (RSF 2000); a topo- isomerase I inhibitor that is semisynthetic derivative of plant alkaloid extracted from bark and leaves of Chinese tree Camptotheca acuminata (current- ly in Phase II clin- ical trial for pan- creatic cancer)
| SuperGen gets exclusive world- wide rights to patented drug in exchange for $2.5M up-front pay- ment (in common stock), ongoing development payments, additional milestone payments (in equity) and royalties (9/97)
|
| Synsorb Biotech Inc. (Canada)
| University of Alberta [Monica Palcic]
| Collaborative research agreement
| Alternative methods for synthesizing clinically relevant carbohydrates as anti-infective agents; disease targets include rotavirus and other viral and bact- erial diseases
| University researchers will get US$0.3M from NRC/NSERC Research Partnership Program for 3-year study; Synsorb gets access to any research data generated (3/97)
|
| Trega Biosciences Inc. Vimrx Pharma- ceuticals Inc.
| Torrey Pines Institute for Mole- cular Studies [Richard Houghten] Columbia Genome Center of Columbia University
| Extension of research agreement Formation of joint venture, Vimrx Genomics Inc.; option on license
| Design and synthe- sis of small-mole- cule combinatorial libraries Mapping, sequenc- ing, gene discovery, and technology development on genomes of humans and other selected organisms; especial- ly for localization and identification of human disease genes
| Extension of 1992 agreement to 4/98; Trega also has option to extend for 3 years beyond that; Trega will fund research and has option for exclusive license to inventions (5/97) Vimrx will own 900f new company, Columbia will own 10%; VIMRx Genomics will pro- vide $30M over 5 years to fund R&D; Vimrx gets option for exclusive license to technology de- veloped by Columbia Genome Center, including certain recently discovered cancer-associated genes (3/97)
|
| Vimrx Genomics Inc. (majority- owned subsidiary of VIMRx Pharma- ceuticals Inc.; joint venture with Colum- bia University)
| Columbia Genome Center (Columbia University) [Riccardo Dalla- Favera]
| Research collaboration
| Development of diagnostics and therapeutics based on cancer genes bcl-6 (regulatory gene overexpressed in 700f patients with non-Hodgkins B cell lymphoma) and mum-1 (regulatory gene over- expressed in many patients with multiple myeloma)
| Vimrx Genomics will identify candidate target sites on genes to intervene in these 2 types of can- cer; gene licenses and patent rights will be transferred from Columbia to Vimrx Genomics; the company will seek strategic alliances for product development (11/97)
|
| Vimrx Pharma- ceuticals Inc.
| Columbia University [David Stern]
| R&D collaboration; license
| Development of Fac- tor IXa inhibitor (IXai, renamed VM20), an anti- coagulant
| Vimrx gets exclusive worldwide license to protein, which it will de- velop for preventing blood clots in patients undergoing cardiopulmon- ary bypass surgery and in hemo- dialysis patients; partners will col- laborate on product development; Columbia gets initial cash payment of $0.1M and a minimum of $0.9M/year for 3 years for R&D; Columbia also gets a percentage of commercial proceeds (3/97)
|
| Vion Pharma- ceuticals Inc.
| Yale University
| Amendment of 2 licensing agreements
| Licenses on 4 anti- viral and anticancer products: TAPET (tumor amplifying protein expression therapy); triapine (ribonucleotide reductase inhibitor); alkylating agent pro- drugs; and antiviral drug B-L-Fd4C
| Vion will decrease its cash pay- ments to Yale associated with sub- licensing agreement milestones; in return, Vion will issue addition- al shares of its common stock to Yale (for an increased equity stake) (8/97)
|
| Visible Genetics Inc. (Canada)
| Agriculture and Agri-Food Canada
| Research collaboration
| Use of Visible Gen- etics¿ DNA sequen- cing technology to develop sequence- based diagnostics for insect and fun- gal pests (targeted natural insecticides)
| 2-year collaboration is part of The Matching Investment Initiative Program in Canada; Visible Gen- etics retains option for exclusive commercial rights to any products (11/97)
|
| Vysys Inc. (IPO pending)
| The University of Chicago, Center for Medical Genetics
| License
| Fluorescence in situ hybridization (FISH) technology for detecting abnor- malities in genes and chromosomes
| Vysys granted Chicago a non- exclusive royalty-bearing license to its patented technology; Chicago will use the technology for gene- tic assessment services for patients (1/97)
|
| Wisconsin Genetics Inc. (subsidiary of Endorex Corp.)
| Wisconsin Alumni Research Foundation [Michael Gould]
| License
| Anticancer drug perillyl alcohol (POH; synthetic monoterpene)
| Wisconsin Genetics gets exclusive worldwide license to drug, which is in National Cancer Institute sponsored Phase I trials; Wisconsin Genetics has option to license additional monoterpene compounds (8/97)
|
|
